
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
POLICY AND PRACTICE REVIEWS article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1529791
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The 2012 American endocrine association guidelines on hypothyroidism were a reiteration of the TSH-T4 Paradigm from the 1970s. They likewise defined hypothyroidism as hypothyroxinemia, assumed that almost all hypothyroidism was primary, and relied upon the TSH test and inactive prohormone T4 for diagnosis and treatment. The guidelines’ authors acknowledged many TSH and other “pitfalls” in the paradigm yet warned physicians against attending to patients’ signs and symptoms and relative free T4 (FT4) and free T3 (FT3) levels—the only means by which to identify and avoid all pitfalls and provide individualized diagnosis and treatment. This inadequate paradigm has distorted medical practice and research for 50 years, including laboratories’ FT4 and FT3 reference ranges. It produces overdiagnosis, underdiagnosis, inadequate treatment, and widespread patient dissatisfaction. In the past 50 years our understanding of thyroid hormone production, transport, metabolism, reception and signaling has increased greatly, as has our appreciation of the importance of optimal T3 effects for health and well-being. Hypothyroidism must be defined physiologically as insufficient T3 effect in some or all tissues. The best indicators of tissue T3 effect are the patient’s signs and symptoms, and the best serum tests are the FT4 and FT3, considered together. The TSH level is not a reliable indicator of T3 status in the untreated state and is oversuppressed by the peak levels that occur with once-daily oral T4 and/or T3. Normalizing an elevated TSH or low FT4 with T4 usually does not produce sufficient, let alone optimal T3 effect and can leave some patients markedly hypothyroid. T4/T3 combination therapy is more physiological and effective than T4 monotherapy and must be guided by clinical criteria, not the TSH. Some patients cannot tolerate more T3 effect due to hypocortisolism, inflammation, and other disorders. There is no substitute for the practice of fully informed clinical medicine.
Keywords: Clinical Medicine, deiodinases, guidelines, Hypocortisolism, Hypothyroidism, paradigm, Reference range, T4/T3 combination therapy
Received: 17 Nov 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Lindner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Henry Hudson Lindner, HormoneRestoration, Tunkhannock, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.